Spots Global Cancer Trial Database for metronomic capecitabine
Every month we try and update this database with for metronomic capecitabine cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) | NCT05044117 | Head and Neck S... | Capecitabine | 18 Years - 70 Years | Sun Yat-sen University | |
| Metronomic Capecitabine in Stage III Gastric Cancer | NCT06313567 | Gastric Cancer | Metronomic cape... Observation | 18 Years - 80 Years | Fudan University | |
| Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors | NCT01203306 | Neuroendocrine ... | bevacizumab + o... | 18 Years - 80 Years | University of Turin, Italy | |
| Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC | NCT01917279 | Breast Neoplasm... Neoplasms by Si... Neoplasm Metast... Breast Diseases Skin Diseases | Docetaxel plus ... Intermittent Ca... Metronomic Cape... | 18 Years - | ChineseAMS | |
| Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer | NCT02767661 | Breast Cancer | Capecitabine Aromatase Inhib... | 18 Years - 70 Years | Sun Yat-sen University | |
| Metronomic Capecitabine in Stage III Gastric Cancer | NCT06313567 | Gastric Cancer | Metronomic cape... Observation | 18 Years - 80 Years | Fudan University | |
| Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma | NCT06093061 | Nasopharyngeal ... | CCRT with Maint... | 21 Years - 99 Years | National Cancer Centre, Singapore | |
| Study of Metronomic Capecitabine and Oxaliplatin Versus XELOX in Egyptian Metastatic Colorectal Cancer Patients | NCT04425564 | Clinical Respon... Toxicity Survival | metronomic XELO... Classic XELOX Blood samples f... | 19 Years - 70 Years | National Cancer Institute, Egypt | |
| Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma | NCT05342792 | Nasopharyngeal ... | PD-1 antibody Capecitabine | 18 Years - 65 Years | Sun Yat-sen University | |
| Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer. | NCT01229813 | Colorectal Canc... | bevacizumab, er... bevacizumab bevacizumab low dose capeci... | 18 Years - | Lund University Hospital | |
| Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma | NCT05342792 | Nasopharyngeal ... | PD-1 antibody Capecitabine | 18 Years - 65 Years | Sun Yat-sen University | |
| Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer. | NCT01229813 | Colorectal Canc... | bevacizumab, er... bevacizumab bevacizumab low dose capeci... | 18 Years - | Lund University Hospital | |
| Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) | NCT05044117 | Head and Neck S... | Capecitabine | 18 Years - 70 Years | Sun Yat-sen University | |
| Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor. | NCT05411380 | Breast Cancer | Tucidinostat Capecitabine Endocrine Thera... | 18 Years - 75 Years | Sun Yat-sen University | |
| Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study) | NCT04571437 | Breast Cancer Estrogen Recept... Metastatic Brea... | Capecitabine Letrozole 2.5mg | 18 Years - 70 Years | Cairo University | |
| Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma | NCT06093061 | Nasopharyngeal ... | CCRT with Maint... | 21 Years - 99 Years | National Cancer Centre, Singapore | |
| Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors | NCT01203306 | Neuroendocrine ... | bevacizumab + o... | 18 Years - 80 Years | University of Turin, Italy | |
| Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors | NCT02736500 | Neuroendocrine ... Gastro Entero P... | 28 GBq 177Lu-DO... 22 GBq 177Lu-DO... | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
